Home > Urology > EAU 2021 > Prostate Cancer > Best of EAU: Updates on imaging and treatment of prostate cancer

Best of EAU: Updates on imaging and treatment of prostate cancer

Presented By
Prof. Alberto Briganti, IRCCS Ospedale San Raffaele, Milan, Italy
Conference
EAU 2021
Trial
STHLM3MRI, TITAN
During the Best of EAU21 session, Prof. Alberto Briganti (IRCCS Ospedale San Raffaele, Milan, Italy) highlighted studies about prostate cancer [1]. The topics ranged from bi-parametric and multiparametric MRI and 18FPSMA-1007 PET-CT scanning to salvage radiotherapy and results on apalutamide from TITAN. The first study Prof. Briganti discussed was STHLM3MRI (NCT03377881), a randomised, population-based, screen-by-intervention diagnostic trial from Sweden. A total of 2,293 men with PSA ≥3 ng/mL or Stockholm3 ≥0.11 were randomly assigned to systematic prostate biopsies or bi-parametric MRI and subsequent targeted plus systematic biopsies. The Stockholm3 test algorithm included clinical variables (i.e. age and previous biopsy status), a single-nucleotide-based genetic score, and measurements of 5 protein levels (i.e. total PSA, free PSA, hK2, MSMB, and MIC-...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on